It offers Singulair for treating asthma, and relief of symptoms of allergic rhinitis; Cozaar/Hyzaar etc. Merck & Co. Inc. has a market cap of $99.52 billion ...
More importantly - from a growth standpoint - the company expects sales for its respiratory drug Singulair to exceed $4.5 billion this year. ...
... have successfully worked together for more than a decade and were pivotal in the discovery of a number of inflammatory drugs, including Singulair(R). ...
The company, which makes the allergy and asthma pill Singulair and the osteoporosis treatment Fosamax, said the net loss amounted to 75 cents a share, ...
... to $6.2 billion, helped by the effects of the weak dollar and strong sales of cholesterol drugs Vytorin and Zetia and allergy treatment Singulair. ...
The Whitehouse, NJ-based maker of allergy and asthma pill Singulair and osteoporosis treatment Fosamaz posted a net loss of 75 cents per share for the ...
The maker of allergy and asthma pill Singulair and osteoporosis treatment Fosamax incurred charges totaling $3.4 billion, or $1.55 a share. ...
Youngsters ages 7 to 14 have the opportunity to participate in the Junior NBA/Junior WNBA Skills Challenge, sponsored by Singulair, Wednesday, Feb. ...
The maker of allergy and asthma pill Singulair and osteoporosis treatment Fosamax said the net loss amounted to 75 cents per share, compared with a year-ago ...
The maker of allergy and asthma pill Singulair and osteoporosis treatment Fosamax said the net loss amounted to 75 cents per share, compared with a year-ago ...